Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

You are aware that there's an entire scientific community, commercial financial world (not millennials with $5k to 'invest'), regulatory agencies, foreign governments (and ours), all keeping an eye on progress within the space, right?

They don't care about BS PR innuendo. They care about concrete and verifiable events/results.

Leo's refusal to commit to dates/times without explanation for everything is an anomaly. It's shady and unprofessional and it doesn't do anything to build trust.

Some general examples of what people could be watching within the space:

-https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker

-https://www.fdatracker.com/covid-19-clinical-trial-tracker/

-https://www.marketwatch.com/investing/pharmaceutical nothing here...

..or here: https://clinicaltrials.gov/ct2/results?cond=&term=Brilacidin+&cntry=&state=&city=&dist=&Search=Search

Concerns related to C19 plays:

https://observer.com/2020/03/coronavirus-covid19-stock-market-biotech-pharma-vaccine-drug/

“There are various biotechs claiming to be advancing a coronavirus vaccine that make similar claims with the medical crisis of the day,” Lichtenfeld told Observer. “When Ebola and Zika were making headlines, some of these companies suddenly had a vaccine development program for those conditions too. Those companies never produced a vaccine and won’t with coronavirus either.”

Innovio and Novavax updates with acknowledgement of delays etc:

-https://finance.yahoo.com/news/novavax-vs-inovio-covid-19-111444245.html

Meanwhile, Novavax’s COVID-19 vaccine candidate is also undergoing a Phase 1/2 trial in the U.S. and Australia. On Nov. 30, the company announced that it expects its pivotal Phase 3 clinical trial in the U.S. and Mexico to begin “in the coming weeks”. The timing of the trial has already been delayed twice.

B. Riley Financial analyst Mayank Mamtani pointed out that Novavax stock has been largely range-bound in 4Q as the delay of the Phase 3 clinical trial in the U.S. has sparked investor concern about execution risk.

I think the market, in general, is looking for confirmation, like they do with every other company within the space. Conjecture isn't helpful with a company that has a track record of never delivering anything other than PR's. You can't take PR's to the bank.

I think people expecting a news release to say what Leo already said - the trial is scheduled to start next week (now last week) - are going to be disappointed. BWDIK?